Melanoma Update and Review: AJCC staging and Adjuvant Treatment

Authors

  • Jennifer Beecker, MD

Abstract

In an era of rapidly changing medical guidelines it is important for dermatologists to be aware of the current recommendations for disease management. This summary article will highlight the ‘need-to-know’ information for the clinical dermatologist on staging, sentinel lymph node biopsy recommendations, and new therapeutic options including adjuvant therapy for the management of patients with melanoma.

Author Biography

Jennifer Beecker, MD

Dr. Jennifer Beecker is a staff dermatologist at The Ottawa Hospital, Assistant Professor at The University of Ottawa. She is a Royal College and American Board of Dermatology certified dermatologist, trained and certified in 3 medical specialties: dermatology, emergency medicine and family medicine. Her interests include medical dermatology, pigmented lesions, in-patient hospital dermatology, and research. She is the Research Director for the Division of Dermatology at The Ottawa Hospital. Dr. Beecker founded the Pigmented Lesion and Melanoma Clinic at the Ottawa Hospital, where she follows patients at high-risk for melanoma with digital dermoscopy and total body photography. Dr. Beecker is the Vice President of the Canadian Dermatology Association’s Board of Directors. She trains medical residents and students and serves on the Executive Committee for the Royal College of Physicians and Surgeons Dermatology Examination.

References

Gershenwald, Jeffrey E, et al. “Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.” CA: a cancer journal for clinicians. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.

NCCN Clinical Practice Guidelines. Melanoma. V1.2017. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.

Faries MB, et al. “Completion dissection or observation for sentinel-node metastasis in melanoma.” New England Journal of Medicine. 2017;376(23):2211-2222.

Agarwala SS, O’Day SJ. “Current and future adjuvant immunotherapies for melanoma: blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach.” Cancer Treatment Reviews. 2011 Apr;37(2):133-42. doi: 10.1016/j.ctrv.2010.06.001. Epub 2010 Jul 16.

Aya A, Tarhini AA. “Adjuvant therapy for melanoma.” Current oncology reports. 2017;19(5)36.

Tarhini AA. “Adjuvant therapy for high-risk melanoma.” American Journal of Hematology/Oncology®. 2014;10(5).

Garbe C, et al. “Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline–Update 2016.” European Journal of Cancer. 2016 Aug;63:201-17. doi: 10.1016/j.ejca.2016.05.005. Epub 2016 Jun 29.

Long GV, et al. “Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.” New England Journal of Medicine. 2017;377(19):1813-1823.

Weber J, et al. “Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.” New England Journal of Medicine. 2017;377(19):1824-1835.

Eggermont AMM, et al. “Adjuvant pembrolizumab versus placebo in resected stage III melanoma.” New England Journal of Medicine. 2018;378(19):1789-1801.

Hauschild A et al. Long-term benefit of adjuvant dabrafenib+ trametinib(D+T) in patients (pts) with resected stage III BRAF V600-mutant melanoma: five-year analysis of COMBI-AD. Presented at ASCO 2020.

Hauschild A, et al. “Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma.” Journal of Clinical Oncology. 2018;36(35):3441.

ESMO 2019: 3-Year Results From CheckMate238: Adjuvant Nivolumab vs Ipilimumab in Advanced Melanoma. https://www.ascopost.com/news/october-2019/3-year-results-from-checkmate-238-adjuvant-nivolumab-vs-ipilimumab-in-advanced-melanoma/.

Eggermont AM, et al. Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: new recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow up. Presented at ASCO 2020.

Whiteman DC, Baade PD, Olsen CM. “More People Die from Thin Melanomas (< 1 mm) than from Thick Melanomas (> 4 mm) in Queensland, Australia.” The Journal of investigative dermatology. 2015 Apr;135(4):1190-1193. doi: 10.1038/jid.2014.452. Epub 2014 Oct 20.

Downloads

Published

2020-07-01

How to Cite

1.
Beecker J. Melanoma Update and Review: AJCC staging and Adjuvant Treatment. Can Dermatol Today [Internet]. 2020 Jul. 1 [cited 2024 May 20];1(3):20-3. Available from: https://canadiandermatologytoday.com/article/view/1-3-beecker

Issue

Volume 1, Issue 3, July 2020

Section

Articles